Platelets Exposed to Elevated Levels of Endogenous Thrombopoietin In Vivo Have a Reduced Response to Megakaryocyte Growth and Development Factor In Vitro

Summary

Thrombopoietin (TPO), or megakaryocyte growth and development factor (MGDF), has been shown to potentiate the sensitivity of normal human platelets to various agonists in vitro. The present study investigated the functional and biochemical properties of platelets from mice rendered thrombocytopenic by sublethal irradiation with regard to the reactivity to recombinant murine MGDF (rmMGDF) in vitro. During the course of reversible thrombocytopenia following irradiation, platelets from irradiated mice which had lower platelet counts and reciprocally higher plasma TPO levels showed lower reactivity to rmMGDF in agonist-induced platelet aggregation. Intravenous injections of recombinant soluble murine c-Mpl (sMpl), which has the ability to capture TPO, after irradiation restored the reactivity of platelets at the platelet nadir to rmMGDF. On the other hand, platelets prepared from normal mice 3 h after a single intravenous injection of pegylated rmMGDF did not respond to rmMGDF. There was a marked decrease in c-Mpl and Janus kinase 2 (JAK2) in platelets from irradiated mice at the platelet nadir. Similar results were observed with platelets from mice administered pegylated rmMGDF. JAK2 was only moderately decreased, however, in platelets from mice given sMpl after irradiation. These results indicate that exposure of platelets to increased endogenous TPO levels in vivo in thrombocytopenic mice leads to a reduction in the platelet reactivity to rmMGDF in vitro. Further, these results suggest that the c-Mpl-mediated signaling pathway, which is essential for the priming effect of rmMGDF, is defective in thrombocytopenic murine platelets.

Keywords

Thrombopoietin - megakaryocyte growth and development factor - platelet - aggregation - c-Mpl

• References

• 1 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg LAJ, Goeddel DV, Eaton DL. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994; 369: 533-8.
• 2 Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O’Hara PJ, Hagen FS, Roth GJ, Foster DC. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-8.
• 3 Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Fortrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC. Promotion of megakaryocyte progenitor expansion and differentiation by the c-MPL ligand thrombopoietin. Nature 1994; 369: 568-71.
• 4 Bartley TD, Bogenberger J, Hunt P, Li Y-S, Lu HS, Martin F, Chang M-S, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu R-Y, Parker VP, Suggs S, Skrine JD, Mereweher LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jakobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Xu W, Castillo JD, Biron J, Cole S, Hu MC-T, Pancifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MPL. Cell 1994; 77: 1117-24.
• 5 Kuter DL, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-8.
• 6 Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Horie K, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H. Purification and characterization of thrombopoietin. J Biochem (Tokyo) 1995; 118: 229-36.
• 7 Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-8.
• 8 Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85: 1719-26.
• 9 Kato T, Horie K, Hagiwara T, Maeda E, Tsumura H, Ohashi H, Miyazaki H. GpIIb/IIIa⁺ subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to human thrombopoietin. Exp Hematol 1996; 24: 1209-14.
• 10 Horie K, Miyazaki H, Hagiwara T, Tahara E, Matsumoto A, Kadoya T, Ogami K, Kato T. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp Hematol 1997; 25: 169-76.
• 11 Hagiwara T, Kodama I, Horie K, Kato T, Miyazaki H. Proliferative properties of human umbilical cord blood megakaryocyte progenitor cells to human thrombopoietin. Exp Hematol 1998; 26: 228-35.
• 12 Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995; 86: 2494-9.
• 13 Papayannopoulou T, Brice M, Farrer D, Kaushansky K. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996; 24: 660-9.
• 14 Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996; 88: 429-36.
• 15 Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, Kaushansky K. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996; 87: 4998-5005.
• 16 Farese A, Hunt P, Boone T, MacVittie T. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86: 54-9.
• 17 Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells 1996; 14: 651-60.
• 18 Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel JW, Steinbrink R, Heccht R, Winters D, Boone T, Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 8 1995; 6: 4486-92.
• 19 Akahori H, Shibuya K, Obuchi M, Nishizawa Y, Tsuji A, Kabaya K, Kusaka M, Ohashi H, Tsumura H, Kato T, Miyazaki H. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996; 94: 722-8.
• 20 Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, Sprugel KH. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice. Exp Hematol 1996; 24: 1238-46.
• 21 Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H. Effect of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells 1996; 14: 678-89.
• 22 Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor im mice. Bone Marrow Transplant 1996; 18: 1035-41.
• 23 Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998; 91: 37-45.
• 24 Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896-1904.
• 25 Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller G-A, de Sauvage FJ, Eaton D. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-8.
• 26 Kuwaki T, Hagiwara T, Yuki C, Kodama I, Kato T, Miyazaki H. Quantitative analysis of thrombopoietin receptors on human megakaryocytes. FEBS Lett 1998; 427: 46-50.
• 27 Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Moore KC, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-61.
• 28 Kato T, Oda A, Inagaki Y, Ohashi H, Matsumoto A, Ozaki K, Miyakawa Y, Watarai H, Fujiu K, Kokubo A, Kadoya T, Ikeda Y, Miyazaki H. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci USA 1997; 94: 4669-74.
• 29 Stefanich E, Senn T, Widmer R, Fratino C, Keller G-A, Fielder PJ. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997; 89: 4063-70.
• 30 Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86: 23-7.
• 31 Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonist-induced aggregation in platelets in vitro. FEBS Lett 1995; 374: 48-52.
• 32 Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-5.
• 33 Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-8.
• 34 Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y. Thrombopoietin induces tyrosine phosphorylation of Stat 3 and Stat 5 in human blood platelets. Blood 1996; 87: 439-46.
• 35 Chen J, Harjacek LH, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054-62.
• 36 Toombs CF, Young CH, Glaspy JA, Vamum BC. Megakaryocyte growth and development factor (MGDF) moderately enhances in vitro platelet aggregation. Thromb Res 1995; 80: 23-33.
• 37 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-70.
• 38 Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol 1997; 54: 225-32.
• 39 Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB. Dose-response effects of pegylated human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet production and function in nonhuman primates. Blood 1996; 88: 511-21.
• 40 Peng J, Friese P, Wolf RF, Harrison P, Downs T, Lok S, Dale GL, Burstein SA. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996; 87: 4158-63.
• 41 Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J, Skrine JD, Knudten A, Chen J, Trail G, Sleeman L, Cole S, Grampp G, Hunt P. Megakaryocyte growth and development factor: Analyses in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-8.
• 42 Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997; 77: 808-14.
• 43 Ku H, Hirayama F, Kato T, Miyazaki H, Aritomi M, Ota Y, D’Andrea AD, Lyman SD, Ogawa M. Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for flt3/flk2. Blood 1996; 88: 4124-31.
• 44 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
• 45 Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: A diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-21.
• 46 Morita H, Tahara T, Matsumoto A, Kato T, Miyazaki H, Ohashi H. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett 1996; 395: 228-34.
• 47 Watanabe K, Takeuchi K, Kawai K, Ikeda Y, Kubota F, Nakamoto H. Automated measurement of reticulated platelets in estimating thrombopoiesis. Eur J Haematol 1995; 54: 163-71.
• 48 Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K, Moore MW, Keller GA, de Sauvage FJ. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997; 90: 3423-9.
• 49 Matzdorff AC, Kemkes-Matthes B, Pralle H. Reactivity of platelets from healthy individuals and from patients with hematologic diseases follwing incubation with pegylated recombinant human megakaryocyte growth and development factor in vitro. Haemostasis 1998; 28: 37-44.
• 50 Ballmaier M, Schulze H, Straub G, Cherkaoui K, Wittner N, Lynen S, Wolters S, Bogenberger J, Welte K. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: Elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90: 612-9.
• 51 Sekine I, Hagiwara T, Miyazaki H, Hirayama K, Dobashi H, Kogawa K, Yoshioka S. Thrombocytopenia with absent radii syndrome: Studies on serum thrombopoietin levels and megakaryopoiesis in vitro. J Pediatr Hematol Oncol 1998; 20: 74-8.
• 52 Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Mutsuzawa Y, Kanakura Y. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031-8.
• 53 Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338: 572-80.
• 54 Usuki K, Iki S, Endo M, Izutsu K, Inoue K, Nishimura T, Urabe A. Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol 1997; 97: 530-7.
• 55 Sato T, Fuse A, Niimi H, Fielder PJ, Avraham H. Binding and regulation of thrombopoietin to human megakaryocytes. Br J Haematol 1998; 100: 704-11.
• 56 Drachman JD, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 1995; 270: 4979-82.
• 57 Yukawa M, Sakon M, Kambayashi JI, Shiba E, Kawasaki T, Ariyoshi H, Mori T. Proteasome and its novel endogenous activator in human platelets. Biochem Biophys Res Commun 1991; 178: 256-62.
• 58 Menard M, Meyers KM, Prieur DJ. Demonstration of secondary lysosomes in bovine megakaryocytes and platelets using acid phosphatase cytochemistry with cesium as a trapping agent. Thromb Haemost 1990; 63: 127-32.